Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D82UVG
|
|||
| Drug Name |
ALPN-202
|
|||
| Drug Type |
Protein
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | |
| Company |
Alpine Immune Sciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytotoxic T-lymphocyte protein 4 (CTLA-4) | Target Info | Inhibitor | [2] |
| Programmed cell death 1 ligand 1 (PD-L1) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Autoimmune thyroid disease | ||||
| Rheumatoid arthritis | ||||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| Reactome | CTLA4 inhibitory signaling | |||
| PD-1 signaling | ||||
| WikiPathways | Vitamin D Receptor Pathway | |||
| T-Cell Receptor and Co-stimulatory Signaling | ||||
| Allograft Rejection | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04186637) An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Alpine Immune Sciences. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.